Nagi Bioscience announced a strategic partnership with Rhino Bio Inc., a leading distributor for next-generation analytical systems in South Korea.

Nagi Bioscience kicks off exclusive Priority Access Program, bringing SydLab™ One to five leading academic labs for C. elegans research.

Nagi Bioscience is thrilled to announce the successful closure of its Series A funding round co-led by Swisscanto and imec.xpand.

Nagi Bioscience is thrilled to announce the successful closure of its Series A funding round co-led by Swisscanto and imec.xpand.

“This certification accredits that Nagi is fully ready to start scaling-up as commercial organization  and to accomplish our mission of accelerating the transition to a new era of biological testing with our state-of-the-art technology.”

We are thrilled to announce the launch into the market of SydLab One: the first end-to-end automated high-content screening of substances on small organisms

Professing the transition to the new era of biological testing as our vision, being selected by the EIC Accelerator program is going to be crucial to make Nagi’s vision a reality.

Nagi Bioscience raises CHF 1.8 Million to accelerate its mission of setting a new standard for testing safety and efficacy of drugs and chemicals.